NeuroBo Pharmaceuticals, Inc. Share Price
Equities
NRBO
US64132R4048
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.14 USD | +2.61% | -6.82% | -15.06% |
17/04 | Sector Update: Health Care Stocks Mixed Wednesday Afternoon | MT |
17/04 | NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 15.4M 1.28B |
---|---|---|---|---|---|
Net income 2024 * | -26M -2.17B | Net income 2025 * | -29M -2.42B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.9
x | P/E ratio 2025 * |
-1.41
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 38.33% |
1 day | +2.61% | ||
1 week | -6.82% | ||
Current month | -23.23% | ||
1 month | -27.65% | ||
3 months | +2.28% | ||
6 months | -8.40% | ||
Current year | -15.06% |
Managers | Title | Age | Since |
---|---|---|---|
Hyung-Heon Kim
CEO | Chief Executive Officer | 47 | 09/21/09 |
Director of Finance/CFO | 66 | 27/23/27 |
Members of the board | Title | Age | Since |
---|---|---|---|
D. Strickland
BRD | Director/Board Member | 77 | 27/22/27 |
Andrew Koven
CHM | Chairman | 66 | 09/21/09 |
Mark Glickman
BRD | Director/Board Member | 58 | 11/23/11 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 3.14 | +2.61% | 17,307 |
25/24/25 | 3.06 | -1.29% | 1,823 |
24/24/24 | 3.1 | +2.65% | 39,360 |
23/24/23 | 3.02 | -3.21% | 42,194 |
22/24/22 | 3.12 | -7.42% | 23,389 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.06% | 15.4M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- NRBO Stock